Cargando…
The Immune Landscape of Chinese Head and Neck Adenoid Cystic Carcinoma and Clinical Implication
Novel systemic agents and effective treatment strategies for recurrence adenoid cystic carcinoma (ACC) of the head and neck are still worthy of further exploration. Here, we analyzed the mutations and expression profiles of 75 Chinese ACC patients, characterized the prognostic value of the immune si...
Autores principales: | Dou, Shengjin, Li, Rongrong, He, Ning, Zhang, Menghuan, Jiang, Wen, Ye, Lulu, Yang, Yining, Zhao, Guodong, Yang, Yadong, Li, Jiang, Chen, Di, Zhu, Guopei |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8450584/ https://www.ncbi.nlm.nih.gov/pubmed/34552580 http://dx.doi.org/10.3389/fimmu.2021.618367 |
Ejemplares similares
-
Apatinib in patients with recurrent or metastatic adenoid cystic carcinoma of the head and neck: a single-arm, phase II prospective study
por: Zhu, Guopei, et al.
Publicado: (2021) -
Combined all‐trans retinoic acid with low‐dose apatinib in treatment of recurrent/metastatic head and neck adenoid cystic carcinoma: A single‐center, secondary analysis of a phase II study
por: Ye, Lulu, et al.
Publicado: (2023) -
Long‐term results of elective mucosal irradiation for head and neck cancer of unknown primary in Chinese population: The EMICUP study
por: Dou, Shengjin, et al.
Publicado: (2020) -
Efficacy and feasibility of Apatinib and S-1 as a novel oral induction therapy in locally advanced head and neck squamous cell carcinoma: an exploratory phase 2 open-label, single-arm trial
por: Jiang, Wen, et al.
Publicado: (2023) -
EGFR Mutation and 11q13 Amplification Are Potential Predictive Biomarkers for Immunotherapy in Head and Neck Squamous Cell Carcinoma
por: Dou, Shengjin, et al.
Publicado: (2022)